European Patent Office

T 0990/96 (Erythro-compounds/NOVARTIS) of 12.02.1998

European Case Law Identifier
ECLI:EP:BA:1998:T099096.19980212
Date of decision
12 February 1998
Case number
T 0990/96
Petition for review of
-
Application number
93106005.7
IPC class
C07C 69/732
Language of proceedings
English
Distribution
Published in the EPO's Official Journal (A)
Other decisions for this case
-
Abstracts for this decision
-
Application title
Acides hept-6-énoiques et heptanoiques substitués sur la position 7 et dérivés de ceux-ci
Applicant name
Novartis AG
Opponent name
Novartis AG
Board
3.3.01
Headnote

1. It is common practice for a person skilled in the art of preparative organic chemistry to (further) purify a compound obtained in a particular chemical manufacturing process according to the prevailing needs and requirements. Since, as a rule, conventional methods for the purification of low molecular organic compounds are within his common general knowledge, a document disclosing a low molecular chemical compound and its manufacture makes normally available this compound to the public in the sense of Article 54 EPC in all desired grades of purity (no. 7 of the reasons for the decision).

2. If a party alleges that this general rule would not be applicable in a particular case, then the burden of proving the existence of such an exceptional situation, e.g. of a situation where all prior attempts to achieve a particular degree of purity by conventional purification processes have failed, lies with the party who alleges such a situation (no. 8 of the reasons for the decision).

Keywords
Novelty (no)
Purity of chemical compound no new element
Catchword
-

ORDER

For these reasons it is decided that:

The appeal is dismissed.